NASDAQ:GRCL • US38406L1035
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GRACELL BIOTECHNOLOGIES-ADR (GRCL).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-02-22 | Stifel | Downgrade | Buy -> Hold |
| 2023-12-27 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2023-12-27 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-12-26 | BTIG | Downgrade | Buy -> Neutral |
| 2023-12-26 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-11-27 | Evercore ISI Group | Initiate | Outperform |
| 2023-10-19 | Stifel | Initiate | Buy |
| 2023-09-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-30 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-29 | Citigroup | Maintains | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-13 | BTIG | Maintains | Buy -> Buy |
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-02-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-06 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-12-08 | HC Wainwright & Co. | Initiate | Buy |
| 2022-09-22 | Citigroup | Initiate | Buy |
| 2022-06-01 | Cantor Fitzgerald | Initiate | Overweight |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 370K | -100.00% | 149.52M | 661.89M 342.68% | 1.629B 146.11% | 2.883B 76.98% | 4.285B 48.63% | ||||||
| EBITDA YoY % growth | -141.46M -137.71% | -192.81M -36.30% | -418.7M -117.16% | -88.626M -35.15% | -95.473M 83.13% | -114.057M -19.47% | -124.135M -8.84% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -146.58M -134.53% | -214.4M -46.27% | -463.57M -116.22% | -100.732M -34.75% | -80.929M 87.04% | -94.784M -17.12% | -110.106M -16.17% | -848.906M -670.99% | -678.31M 20.10% | -327.978M 51.65% | 435.36M 232.74% | 1.322B 203.66% | |
| Operating Margin | N/A | N/A | -125,289.19% | N/A | N/A | N/A | N/A | -567.75% | -102.48% | -20.13% | 15.10% | 30.85% | |
| EPS YoY % growth | N/A | N/A | -1.05 -2.28% | -0.69 -23.81% | -0.91 29.78% | -0.55 39.39% | -1.14 -106.45% | -4.02 -251.68% | -3.09 23.18% | -2.43 21.11% | 0.63 126.00% | 4.33 584.57% |
All data in CNY
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 52.40% | -0.21 38.80% | -0.21 28.60% | -0.22 -124.40% | -0.22 -57.14% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -19.207M 78.78% | -21.357M | -23.721M 79.47% | -26.323M | N/A |
| EBIT Q2Q % growth | -19.236M 87.12% | -22.508M 86.49% | -22.95M 83.74% | -23.46M -5.50% | -23.984M -24.68% |
All data in CNY
15 analysts have analysed GRCL and the average price target is 10.76 USD. This implies a price increase of 4.99% is expected in the next year compared to the current price of 10.25.
GRACELL BIOTECHNOLOGIES-ADR (GRCL) will report earnings on 2024-03-11, after the market close.
The consensus EPS estimate for the next earnings of GRACELL BIOTECHNOLOGIES-ADR (GRCL) is -0.14 USD and the consensus revenue estimate is 0 USD.
The consensus rating for GRACELL BIOTECHNOLOGIES-ADR (GRCL) is 78.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.